Effects of the sodium-glucose cotransporter 2 inhibitor empagliflozin on vascular function in patients with chronic heart failure

Kolwelter J, Bosch A, Jung S, Stabel L, Kannenkeril D, Ott C, Bramlage P, Schiffer M, Achenbach S, Schmieder R (2021)

Publication Type: Journal article

Publication year: 2021

Journal

ESC Heart Failure Wiley

DOI: 10.1002/ehf2.13622

Abstract

Aims Impairment of vascular function contributes to the progression of chronic heart failure (HF) by increasing the afterload. Treatment with selective sodium-glucose cotransporter 2 (SGLT2) inhibitors improves the prognosis of HF, but the precise mechanisms remain unclear. The aim of this study was to analyse the effect of empagliflozin on vascular function in patients with HF.

Authors with CRIS profile

Julie Kolwelter Department of Medicine 2 – Cardiology and Angiology Agnes Bosch Department of Medicine 4 – Nephrology and Hypertension Lena Stabel Professur für Innere Medizin (Nephrologie) Christian Ott Department of Medicine 4 – Nephrology and Hypertension Mario Schiffer Lehrstuhl für Innere Medizin IV Stephan Achenbach Lehrstuhl für Innere Medizin II Roland Schmieder Professur für Innere Medizin (Nephrologie)

Involved external institutions

Institut für Pharmakologie und präventive Medizin (IPPMed GmbH) DE Germany (DE)

How to cite

APA:

Kolwelter, J., Bosch, A., Jung, S., Stabel, L., Kannenkeril, D., Ott, C.,... Schmieder, R. (2021). Effects of the sodium-glucose cotransporter 2 inhibitor empagliflozin on vascular function in patients with chronic heart failure. ESC Heart Failure. https://dx.doi.org/10.1002/ehf2.13622

MLA:

Kolwelter, Julie, et al. "Effects of the sodium-glucose cotransporter 2 inhibitor empagliflozin on vascular function in patients with chronic heart failure." ESC Heart Failure (2021).

BibTeX: Download